News

Abraxis Pharmaceutical Products (APP) currently manufactures and distributes Oxytocin in 1ml and 10ml vials. The company will distribute the larger size in multi-dose vials with latex-free stoppers and

The agreement provides Archemix with access to approximately four hundred issued and pending Isis patents covering proprietary chemistries, analytical methods and manufacturing methods related to the research, development

GSK has agreed to waive royalties on the basis that Apotex’s triple combination generic ARV will be supplied on a no profit basis. The drug contains two molecules

In the preclinical toxicology studies, the compound was generally safe and well tolerated in animals at dose levels that are expected to exceed a therapeutically relevant dose. In

The supplemental biologics license application (sBLA) is based on data a double-blind, randomized trial that consisted of three periods; the first period involved a four-month open-label lead-in treatment

The National Institutes of Health (NIH), has been funding Dynavax’s research since 2003, which focuses on a new vaccine that incorporates a second- generation TLR9 agonist and the

With the exception of these countries (Denmark, Finland, Iceland, Norway and Sweden), Wyeth markets BeneFIX around the world. Under the terms of the agreement, Biovitrum will receive a

Viracept was recalled in June and has now had its license put on hold. The European Medicines Agency (EMEA), which handles drug safety, recommended the Commission suspend Roche’s

The drug, PRX-08066, is a novel 5-HT2B antagonist that the company believes represents a new mechanism of action for treating pulmonary hypertension (PH). Epix said that PRX-08066 resulted